News

The study indicates which biomarkers should be prioritized to predict neovascular AMD and geographic atrophy.

Investigators believe the connection may account for a substantial number of anemia cases in children.

Angel Goenawan, MD, shared findings from a meta-analysis of surgical and nonsurgical clinical trials.

Individuals treated with ezetimibe shortly after myocardial infarction experience an improved prognosis versus those who receive delayed treatment or none at all.

This network meta-analysis compares the relative effectiveness and safety of different monotherapies for patients living with alopecia areata.

Combining FESS with selective vidian neurectomy improved long-term nasal symptom control, especially nasal itching, in CRSwNP, allergic rhinitis, and asthma.

Liver transplant recipients with infective endocarditis had greater odds of in-hospital mortality, ICU admission, and longer length of stay.

Side effects of baricitinib were well within safety parameters, indicating the drug’s viability as a alopecia treatment for adults.

In this episode, experts discuss practical guidance for screening for presymptomatic type 1 diabetes with Rifka Schulman-Rosenbaum, MD.

Nawsabah Noor, MBBS, discussed how her team developed novel AI training to reduce racial bias in diagnosing mpox lesions.

A first-of-its-kind medication developed by Atsena Therapeutics, ATSN-201 has already received three other FDA designations.

This systematic review highlights current research on ruxolitinib’s off-label use in dermatology, specifically for conditions such as alopecia and psoriasis.

Ultrasound showed no significant dermis thickness difference at the cubital fossa, yet dust mite-sensitized kids had signs of allergen-driven skin changes.

Valerie Louis outlined her ASKmeGOC study and the electronic tool her team developed to help preemptively record preferences.

Tumlin reviews findings from a posthoc analysis of DUPLEX demonstrating sparsentan’s impact on partial remission, complete remission, and kidney failure.

Zehavi Horowitz-Kugler, MD, and Ran Shaul discussed an AI model K Health developed and evaluated in a virtual urgent care clinic.

Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.

These data on 5α-reductase inhibitors highlight impacts on patients with benign prostatic hyperplasia or androgenic alopecia.

Adrienne Poon, MD, MPH, discussed early findings from a community health needs survey of AAPI populations.

In children with septic shock, norepinephrine as the first vasoactive agent was linked to lower 30-day mortality than epinephrine, with no renal outcome difference.

Black patients disproportionately started dialysis at low-quality facilities and were less likely to have nephrologists with high-quality primary facilities.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

The new tablet formulation of maralixibat for the treatment of cholestatic pruritus in patients with ALGS and PFIC is expected to be available in June.

In this Q&A, Augsten discusses treatment strategies, challenges, and non-pharmacological interventions for schizophrenia and bipolar I disorder based on recent survey findings.

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.